Literature DB >> 34721719

68Ga-FAPI-46 PET/MR Detects Recurrent Cholangiocarcinoma and Intraductal Papillary Mucinous Neoplasm in a Patient Showing Increasing CEA with Negative 18F-FDG PET/CT and Conventional CT.

Dheeratama Siripongsatian1, Chetsadaporn Promteangtrong1, Anchisa Kunawudhi1, Peerapon Kiatkittikul1, Chanisa Chotipanich1.   

Abstract

A patient with intrahepatic cholangiocarcinoma who underwent hepatic resection with completed neoadjuvant chemotherapy presented with increased CEA levels. Previous whole abdominal and chest CT scan revealed no evidence of local recurrence or metastasis. 68 Ga-FAPI-46 PET showed significantly higher tumor-to-background contrast of recurrent tumor and nodal metastasis, which were undetectable in the FDG PET or conventional CT scan. These findings changed patient management. Larger studies with histopathological correlation and comparisons with other imaging modalities are required to validate the diagnostic performance. Moreover, a cystic lesion with FAPI uptake at the neck to the proximal body of the pancreas without FDG uptake is also incidentally noted. Differential diagnoses include sided branch IPMN and serous cystadenoma. © Korean Society of Nuclear Medicine 2021.

Entities:  

Keywords:  Cholangiocarcinoma; FDG; Fibroblast activation protein; Intraductal papillary mucinous neoplasm (IPMN); PET/CT; PET/MRI

Year:  2021        PMID: 34721719      PMCID: PMC8517048          DOI: 10.1007/s13139-021-00712-8

Source DB:  PubMed          Journal:  Nucl Med Mol Imaging        ISSN: 1869-3474


  15 in total

Review 1.  Primary cystic neoplasms of the pancreas. Neoplastic disorders of emerging importance-current state-of-the-art and unanswered questions.

Authors:  Michael G Sarr; Michel Murr; Thomas C Smyrk; Charles J Yeo; Carlos Fernandez-del-Castillo; Robert H Hawes; Patrick C Freeny
Journal:  J Gastrointest Surg       Date:  2003 Mar-Apr       Impact factor: 3.452

Review 2.  Targeting cholangiocarcinoma.

Authors:  Joachim C Mertens; Sumera Rizvi; Gregory J Gores
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-08-24       Impact factor: 5.187

3.  Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers.

Authors:  P Garin-Chesa; L J Old; W J Rettig
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

4.  Imaging fibroblast activation protein in liver cancer: a single-center post hoc retrospective analysis to compare [68Ga]Ga-FAPI-04 PET/CT versus MRI and [18F]-FDG PET/CT.

Authors:  Wei Guo; Yizhen Pang; Lanlin Yao; Liang Zhao; Chunlei Fan; Jingpeng Ke; Ping Guo; Bing Hao; Hao Fu; Chengrong Xie; Qin Lin; Hua Wu; Long Sun; Haojun Chen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-11-11       Impact factor: 9.236

Review 5.  Rationale behind targeting fibroblast activation protein-expressing carcinoma-associated fibroblasts as a novel chemotherapeutic strategy.

Authors:  W Nathaniel Brennen; John T Isaacs; Samuel R Denmeade
Journal:  Mol Cancer Ther       Date:  2012-02       Impact factor: 6.261

6.  18F-fluorodeoxyglucose positron emission tomography influences management decisions in patients with biliary cancer.

Authors:  Carlos U Corvera; Leslie H Blumgart; Timothy Akhurst; Ronald P DeMatteo; Michael D'Angelica; Yuman Fong; William Robert Jarnagin
Journal:  J Am Coll Surg       Date:  2007-10-01       Impact factor: 6.113

Review 7.  Cholangiocarcinoma: update and future perspectives.

Authors:  Manuela Gatto; Maria Consiglia Bragazzi; Rossella Semeraro; Cristina Napoli; Raffaele Gentile; Alessia Torrice; Eugenio Gaudio; Domenico Alvaro
Journal:  Dig Liver Dis       Date:  2010-01-22       Impact factor: 4.088

Review 8.  Cancer associated fibroblasts in cancer pathogenesis.

Authors:  Omar E Franco; Aubie K Shaw; Douglas W Strand; Simon W Hayward
Journal:  Semin Cell Dev Biol       Date:  2009-11-05       Impact factor: 7.727

9.  Comparison of [68Ga]Ga-DOTA-FAPI-04 and [18F] FDG PET/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer.

Authors:  Haojun Chen; Yizhen Pang; Jingxun Wu; Liang Zhao; Bing Hao; Jing Wu; Jihong Wei; Siming Wu; Long Zhao; Zuoming Luo; Xuehua Lin; Chengrong Xie; Long Sun; Qin Lin; Hua Wu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-03-28       Impact factor: 9.236

10.  Clinicopathological presentation of varying 18F-FDG uptake and expression of glucose transporter 1 and hexokinase II in cases of hepatocellular carcinoma and cholangiocellular carcinoma.

Authors:  Bishnuhari Paudyal; Noboru Oriuchi; Pramila Paudyal; Yoshito Tsushima; Tetsuya Higuchi; Mitsuyuki Miyakubo; Tomohiro Ishikita; Takashi Nakajima; Keigo Endo
Journal:  Ann Nucl Med       Date:  2008-01       Impact factor: 2.668

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.